[1]王秀丽.阿奇霉素序贯治疗联合特布他林雾化吸入治疗小儿支原体肺炎的临床疗效[J].徐州医科大学学报,2020,40(11):839-842.[doi:10.3969/j.issn.2096-3882.2020.11.013]
点击复制

阿奇霉素序贯治疗联合特布他林雾化吸入治疗小儿支原体肺炎的临床疗效()
分享到:

《徐州医科大学学报》[ISSN:2096-3882/CN:32-1875/R]

卷:
40
期数:
2020年11期
页码:
839-842
栏目:
出版日期:
2020-11-25

文章信息/Info

Title:
Observation of Clinical Effectiveness and Security of Azithromycin Sequential Therapy Combined with Terbutaline in the Treatment of Mycoplasma Pneumonia
作者:
王秀丽
安徽省妇幼保健院儿科,安徽 合肥 230031
关键词:
阿奇霉素 雾化吸入 序贯治疗 支原体肺炎
DOI:
10.3969/j.issn.2096-3882.2020.11.013
文献标志码:
A
摘要:
目的 评估阿奇霉素序贯治疗联合特布他林雾化吸入治疗小儿支原体肺炎的临床疗效.方法 选取2017年9月—2018年7月于安徽省妇幼保健院治疗的小儿支原体肺炎患儿,共60例.根据随机数字法将患儿分为观察组和对照组,每组30例.观察组给予阿奇霉素序贯治疗联合特布他林雾化吸入治疗,对照组给予红霉素静脉滴注治疗联合阿奇霉素口服治疗.比较2组患儿的治疗总有效率,观察2组患儿临床体征消失时间,比较治疗前后血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平的变化,记录不良反应发生情况.结果 治疗后,观察组的总有效率和临床症状消失时间与对照组比较,差异无统计学意义(P>0.05).治疗后,2组患儿血清TNF-α和IL-6水平较治疗前均明显下降(P<0.05),且观察组TNF-α和IL-6水平低于对照组,但差异无统计学意义(P>0.05).观察组患儿的不良反应总发生率显著低于对照组,差异有统计学意义(P<0.05).结论 阿奇霉素序贯治疗联合特布他林雾化吸入治疗小儿支原体肺炎疗效显著,可明显改善患儿的细胞因子水平,较快缓解患儿的临床症状,安全性更高.
Abstract:
[ABSTRACT] ob<x>jective: To analyse clinical effectiveness and security of azithromycin sequential therapy combined with terbutaline in the treatment of mycoplasma pneumonia by compare. Methods: The subjects of this study were 60 children with mycoplasma pneumonia admitted to our hospital from September 2017 to July 2018,Patients were divided into observation group and control group according to the random number method, with 30 cases each. Patients in the observation group were given sequential treatment of azithromycin combined with nebutamine inhalation, and patients in the control group were given erythromycin intravenous infusion therapy combined with nebutamine inhalation, Clinical efficacy and safety of the two groups were compared, That is, the disappearance time and adverse reactions of related clinical manifestations after treatment (cough, fever, wheezing, lung rumble) , as well as before and after treatment serum tumor necrosis factor alpha (TNF -α), interleukin 6 (IL-6) - cytokines such as the change of the level. Results: The total effective treatment rate for the observation group was 90.00%, the control group was 80.00%, and the difference was no statistically significant (χ2 =0.16,P=0.69); the disappearance time of cough, fever, wheezing and lung rumble was shorter in the observation group than in the control group, and the difference was no statistically significant (P>0.05); in the two groups after treatment in patients with serum TNF-α, IL-6 were significantly lower, comparative differences was no statistically significant (P>0.05); the total incidence of adverse reactions was 13.33% in the observation group and 36.67% in the control group;the difference between the two groups was statistically significant(χ2=4.36,P=0.04). Results: For the treatment of mycoplasma pneumonia in children, azithromycin sequential therapy combined with terbutaline atomization inhalation therapy has a significant effect, significantly improving the cytokine level of the patients, rapidly alleviating the clinical symptoms of the patients, and has a higher safety.Key words: Azithromycin; Terbutaline; Sequential Therapy; Mycoplasma Pneumonia
更新日期/Last Update: 2020-12-15